Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...